The role of exome data reanalysis in clarifying STXBP3 associated inflammatory bowel disease and hearing loss
Status PubMed-not-MEDLINE Jazyk angličtina Země Velká Británie, Anglie Médium electronic-ecollection
Typ dokumentu časopisecké články
PubMed
40575033
PubMed Central
PMC12199908
DOI
10.1093/gastro/goaf053
PII: goaf053
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Zobrazit více v PubMed
Nameirakpam J, Rikhi R, Rawat SS et al. Genetics on early onset inflammatory bowel disease: an update. Genes Dis 2020;7:93–106. PubMed PMC
Ouahed J, Kelsen JR, Spessott WA et al. Variants in PubMed PMC
Levine A, Griffiths A, Markowitz J et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314–21. PubMed
Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–12. PubMed
Turner D, Griffiths AM, Walters TD et al. Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012;18:55–62. PubMed
Sturm M, Admard J, Schütz L et al. IMGAG/megSAP (Version 2024_09). Zenodo, 2024. 10.5281/zenodo.13744183 DOI
Richards S, Aziz N, Bale S et al. ; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24. PubMed PMC
Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factoragents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:1709–18. PubMed
Rosario M, Dirks NL, Milch C et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet 2017;56:1287–301. PubMed PMC
Colombel J-F, Ungaro RC, Sands BE et al. Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn’s disease (EXPLORER). Clin Gastroenterol Hepatol 2024;22:1487–96.e12. PubMed